NeuroScientific Biopharmaceuticals (NSB) Investor presentation summary

Corporate and capital snapshot

• As at November 2026: share price A$0.05; market capitalisation ~A$19.5m; cash ~A$3.9m at 30 September 2026.

• Capital structure: 389.72m ordinary shares, 1.50m performance shares and 43.25m options.

Market opportunity and positioning

• Global Crohn’s disease market cited at US$13B+; 6–8m patients globally, with 30% not responding to standard therapies.

• StemSmart targets patients who have failed at least two mechanisms, positioning it as a new therapy line after biologic failure.

• Fistulising disease can cause severe complications, and surgery may become inevitable when treatment options are limited.

StemSmart technology and clinical evidence

• Purpose-built mesenchymal stem cell therapy for severe inflammation; proprietary activation process, patented technology and production under TGA accreditation.

• Open-label Phase 2 luminal study in 18 anti-TNF-refractory patients reported 78% clinical response, 44% remission and 44% endoscopic improvement at Day 42.

• Crohn’s Special Access results in fistulising patients reported an 80% response rate in five adults; CDAI, PDAI and IBDQ improved in all five, with MRI trending toward fistula healing.

• Prior studies reported no serious adverse events attributed to MSCs; the Phase 2 study was single-arm and had no placebo control.